Cefepime
Brand names: Maxipime
Cefepime is an intravenous fourth-generation cephalosporin antibiotic used for serious infections including hospital-acquired pneumonia, complicated urinary tract and intra-abdominal infections and febrile neutropenia.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is bactericidal, binding penicillin-binding proteins to inhibit cell-wall synthesis, and is relatively stable to many beta-lactamases, giving broad Gram-negative and Gram-positive cover.
Prescribing in practice
- Doses must be reduced according to renal function, as accumulation in renal impairment is associated with neurotoxicity including encephalopathy, myoclonus and non-convulsive status epilepticus.
- Avoid in patients with a history of immediate or severe hypersensitivity to penicillins or cephalosporins.
- It retains useful activity against Pseudomonas aeruginosa, which informs its place in empirical regimens.
Monitoring
Monitor renal function to guide dosing and watch for new neurological signs such as confusion or myoclonus, particularly in renal impairment.
Counselling the patient
- This antibiotic is given into a vein, with the dose adjusted to your kidney function.
- Tell staff straight away about any confusion, muscle twitching or fits.
- Report any rash, swelling or difficulty breathing.
Evidence & guidelines
The MHRA and SPC highlight the risk of serious neurological reactions with cefepime when doses are not adjusted in renal impairment.
Reference: BSAC; UKHSA; MHRA Drug Safety Update; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023